Who owns Relay Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of RLAY from SEC Form 13F filings across 262 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 262 institutions disclosed 253.0M shares of Relay Therapeutics, Inc. worth $4.57B — about 115.5% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
262
13F holders
$4.57B
value, 2026 filers
115.5%
of shares outstanding (253.0M sh)
35
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of RLAY's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 24.2M | $437.5M | 0.0% | 11.1% | +20.5% |
| 2 | SB INVESTMENT ADVISERS (UK) LTD | 21.9M | $395.4M | 6.4% | 10% | -21.5% |
| 3 | T. Rowe Price Investment Management, Inc. | 17.9M | $322.5M | 0.2% | 8.2% | +832.8% |
| 4 | BlackRock, Inc. | 16.7M | $301.4M | 0.0% | 7.6% | +9.2% |
| 5 | Casdin Capital, LLC | 16.0M | $289.4M | 12.6% | 7.3% | 0.0% |
| 6 | PERCEPTIVE ADVISORS LLC | 12.7M | $229.8M | 4.0% | 5.8% | -9.8% |
| 7 | Commodore Capital LP | 12.0M | $216.6M | 16.8% | 5.5% | 0.0% |
| 8 | STATE STREET CORP | 9.2M | $165.2M | 0.0% | 4.2% | -9.6% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 9.0M | $162.7M | 0.0% | 4.1% | +0.5% |
| 10 | Nextech Invest Ltd. | 6.8M | $122.3M | 5.5% | 3.1% | 0.0% |
| 11 | PRICE T ROWE ASSOCIATES INC /MD/ | 6.6M | $119.7M | 0.0% | 3% | -14.0% |
| 12 | Bellevue Group AG | 6.2M | $111.7M | 2.3% | 2.8% | 0.0% |
| 13 | GEODE CAPITAL MANAGEMENT, LLC | 5.1M | $92.1M | 0.0% | 2.3% | +8.0% |
| 14 | ALLIANCEBERNSTEIN L.P. | 3.9M | $70.7M | 0.0% | 1.8% | -4.3% |
| 15 | TCG Crossover Management, LLC | 3.8M | $68.3M | 1.9% | 1.7% | -11.5% |
| 16 | WESTFIELD CAPITAL MANAGEMENT CO LP | 3.6M | $65.2M | 0.2% | 1.6% | +8.1% |
| 17 | Siren, L.L.C. | 3.3M | $58.9M | 1.4% | 1.5% | -10.6% |
| 18 | DIMENSIONAL FUND ADVISORS LP | 3.2M | $57.3M | 0.0% | 1.4% | +1.6% |
| 19 | BANK OF AMERICA CORP /DE/ | 3.1M | $56.0M | 0.0% | 1.4% | +15.1% |
| 20 | Spruce Street Capital LP | 3.0M | $53.9M | 8.6% | 1.4% | 0.0% |
| 21 | BAKER BROS. ADVISORS LP | 2.8M | $51.0M | 0.2% | 1.3% | 0.0% |
| 22 | Kynam Capital Management, LP | 2.8M | $49.7M | 2.7% | 1.3% | -16.6% |
| 23 | MORGAN STANLEY | 2.6M | $46.8M | 0.0% | 1.2% | -32.7% |
| 24 | MPM BIOIMPACT LLC | 2.4M | $42.8M | 3.2% | 1.1% | -1.9% |
| 25 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.3M | $41.9M | 0.0% | 1.1% | -19.7% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.